ClinicalTrials.gg

Program

AZD1613

A development code. Also written as “AZD1613 - Part B”.

Its studies are mostly in Polycystic Kidney, Autosomal Dominant, led by AstraZeneca.

Furthest: phase 1, since May 28, 20252 company-led studies, 2 open or runningNext primary completion: Nov 16, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca22 open or runningphase 1since May 28, 2025May 28, 2025Nov 16, 2026phase 1 · NCT06995820
  • Named in AstraZeneca’s own pipeline as AZD1613, phase 1, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 28, 2025First study: phase 1 study in HealthyFirst studyNCT06995820 · 72 enrolled · United States
  2. Oct 23, 2025Phase 1 study in Polycystic Kidney, Autosomal DominantNCT07228364 · 40 planned · United States, China, United Kingdom

Ahead

  1. Nov 16, 2026Primary completion: phase 1 study in HealthyNCT06995820
  2. May 22, 2027Primary completion: phase 1 study in Polycystic Kidney, Autosomal DominantNCT07228364

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07228364Polycystic Kidney, Autosomal Dominant · United States, China, United Kingdom1RecruitingMay 22, 202740
NCT06995820Healthy · United States1Active, not recruitingNov 16, 202672

How it is read

Names in the registry

  • “AZD1613 - Part B”, 1 entry
  • “AZD1613”, 1 entry

Codes read as this program: AZD1613.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.